Stem Cell Rev Rep. 2022 Dec 14. doi: 10.1007/s12015-022-10489-8. Online ahead of print.
NO ABSTRACT
PMID:36515764 | DOI:10.1007/s12015-022-10489-8
Feeds
4301 items (4301 unread) in 74 feeds
Acinar Cell Carcinoma
(73 unread)
Acinic Cell Carcinoma
(53 unread)
Adenoid Cystic Carcinoma
(264 unread)
Adrenal Gland Cancer
(299 unread)
Ampulla Of Vater
(55 unread)
Anal Cancer
(374 unread)
Angiosarcoma
(75 unread)
Appendix Cancer
(95 unread)
Bile Duct Cancer
(420 unread)
Brain and CNS
(464 unread)
Carcinoid
(70 unread)
Endocrine/Neuroendocrine
(637 unread)
Gall Bladder Cancer
(90 unread)
Hemangioendothelioma
(149 unread)
Hepatoblastoma
(67 unread)
Pancreas
(72 unread)
Phyllodes
(61 unread)
PMP and Mucinous Tumors
(79 unread)
Rhabdomyosarcoma
(96 unread)
Sarcoma
(808 unread)
Unread items (100)
PubMed - Sarcoma
-
Amyotrophic Lateral Sclerosis, FUS and Protein Synthesis Defects
Fetched: December 16th, 2022, 5:02am GMT by Amanda Faria Assoni
-
A 20.5 cm Malignant Peripheral Nerve Sheath Tumor of the Anterior Mediastinum Showing Response to Neoadjuvant Therapy
Fetched: December 16th, 2022, 5:02am GMT by Malika P Ganguli
Cureus. 2022 Nov 9;14(11):e31299. doi: 10.7759/cureus.31299. eCollection 2022 Nov.
NO ABSTRACT
PMID:36514670 | PMC:PMC9733815 | DOI:10.7759/cureus.31299
-
Disseminated Peritoneal Leiomyomatosis With Unusual Lung Mesenchymal Malignant Transformation
Fetched: December 16th, 2022, 5:02am GMT by Huda E Buhusayyen
Cureus. 2022 Nov 9;14(11):e31307. doi: 10.7759/cureus.31307. eCollection 2022 Nov.
NO ABSTRACT
PMID:36514668 | PMC:PMC9733794 | DOI:10.7759/cureus.31307
-
Separation Surgery, Fixation With Carbon-Fiber Implants, and Stereotactic Body Radiotherapy for Oligometastatic Spinal Disease
Fetched: December 16th, 2022, 5:02am GMT by Richard Galloway
Cureus. 2022 Nov 11;14(11):e31370. doi: 10.7759/cureus.31370. eCollection 2022 Nov.
NO ABSTRACT
PMID:36514641 | PMC:PMC9741859 | DOI:10.7759/cureus.31370
-
Herpes Simplex Virus Esophagitis as a Presentation of Febrile Neutropenia: A Case Report
Fetched: December 16th, 2022, 5:02am GMT by Sammy Droubi
Cureus. 2022 Nov 9;14(11):e31280. doi: 10.7759/cureus.31280. eCollection 2022 Nov.
NO ABSTRACT
PMID:36514600 | PMC:PMC9732914 | DOI:10.7759/cureus.31280
-
Endoscopic Management of Malignant Tumors of Paranasal Sinus and Nasal Cavity: An Institutional Experience
Fetched: December 16th, 2022, 5:02am GMT by Rajat Jain
Indian J Otolaryngol Head Neck Surg. 2022 Dec;74(4):564-574. doi: 10.1007/s12070-022-03141-x. Epub 2022 Sep 9.
NO ABSTRACT
PMID:36514438 | PMC:PMC9741682 | DOI:10.1007/s12070-022-03141-x
-
Primary Pulmonary Hyalinizing Clear Cell Carcinoma: Case Series With Review of Literature
Fetched: December 16th, 2022, 5:02am GMT by Shilpi Thakur
Int J Surg Pathol. 2022 Dec 13:10668969221137516. doi: 10.1177/10668969221137516. Online ahead of print.
NO ABSTRACT
PMID:36514272 | DOI:10.1177/10668969221137516
-
Comprehensive genomic profiling of a unique liposarcoma arising in a patient with Li-Fraumeni syndrome and the novel detection of c-myc amplification: a case report
Fetched: December 16th, 2022, 5:02am GMT by Hirofumi Watanabe
Diagn Pathol. 2022 Dec 13;17(1):93. doi: 10.1186/s13000-022-01264-x.
NO ABSTRACT
PMID:36514176 | PMC:PMC9746193 | DOI:10.1186/s13000-022-01264-x
-
Letrozole in Uterine Leiomyosarcoma
Posted: December 14th, 2022, 3:00pm GMT
Condition: Uterine Leiomyosarcoma
Intervention: Drug: Letrozole
Sponsor: GOG Foundation
Not yet recruiting -
Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi Sarcoma
Posted: December 12th, 2022, 3:00pm GMT
Condition: Refractory HIV Associated Kaposi Sarcoma
Intervention: Drug: Dostarlimab in Combination Antiretroviral Therapy
Sponsor: Imperial College London
Not yet recruiting -
SPEARHEAD-3 Pediatric Study
Posted: December 8th, 2022, 3:00pm GMT
Conditions: Synovial Sarcoma; Malignant Peripheral Nerve Sheath Tumor (MPNST); Neuroblastoma; Osteosarcoma
Intervention: Genetic: Afamitresgene autoleucel
Sponsor: Adaptimmune
Not yet recruiting -
Undifferentiated Embryonal Sarcoma of the Liver: Evaluation of the Relapse Profile According to the Therapies Administered
Posted: December 7th, 2022, 3:00pm GMT
Condition: Hepatic Sarcoma
Intervention:
Sponsor: University Hospital, Strasbourg, France
Recruiting -
A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue
Posted: December 2nd, 2022, 3:00pm GMT
Conditions: Pediatric Sarcoma, Refractory; Pediatric Sarcoma, Relapsed
Intervention: Biological: GEM/DOX + TGFBi expanded NK cells
Sponsor: Nationwide Children's Hospital
Recruiting -
Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
Posted: December 1st, 2022, 3:00pm GMT
Conditions: Locally Advanced Leiomyosarcoma; Metastatic Leiomyosarcoma; Stage III Uterine Corpus Leiomyosarcoma AJCC v8; Stage IV Uterine Corpus Leiomyosarcoma AJCC v8; Unresectable Leiomyosarcoma; Uterine Corpus Leiomyosarcoma
Interventions: Drug: Olaparib; Drug: Temozolomide; Drug: Trabectedin; Drug: Pazopanib
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting -
Influence of Nutritional Status on Oncologic and Operative Outcome in Patients Operated for Retroperitoneal Sarcoma
Posted: November 30th, 2022, 3:00pm GMT
Conditions: Retroperitoneal Sarcoma; Body Composition; Malnutrition; Sarcopenia; Sarcopenic Obesity; Myosteatosis
Interventions: Other: Measurement of body composition with computed tomography (CT); Diagnostic Test: GLIM malnutrition criteria; Diagnostic Test: EWGSOP2 sarcopenia criteria; Diagnostic Test: ESPEN-EASO criteria for sarcopenic obesity; Diagnostic Test: Prognostic Nutritional Index (PNI); Diagnostic Test: The high-sensitivity modified Glasgow prognostic score
Sponsor: Institute of Oncology Ljubljana
Recruiting -
A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
Posted: November 18th, 2022, 3:00pm GMT
Conditions: Soft Tissue Sarcoma; Bone Sarcoma
Interventions: Drug: Cyclophosphamide; Drug: attIL2-T cells
Sponsor: M.D. Anderson Cancer Center
Not yet recruiting -
Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma
Posted: November 17th, 2022, 3:00pm GMT
Condition: Advanced Soft-tissue Sarcoma
Intervention: Biological: NY-ESO-1 TCR-T
Sponsor: Shenzhen University General Hospital
Recruiting -
EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
Posted: November 17th, 2022, 3:00pm GMT
Conditions: Ovarian Carcinosarcoma; Uterine Carcinosarcoma
Interventions: Drug: Eribulin Mesylate; Drug: Pembrolizumab
Sponsors: Australia New Zealand Gynaecological Oncology Group; Eisai Inc.; Merck Sharp & Dohme LLC
Not yet recruiting -
Lenvatinib for Advanced Bone and Soft Tissue Sarcoma
Posted: November 16th, 2022, 3:00pm GMT
Conditions: Effectiveness; Sexuality
Intervention: Drug: Lenvatinib mesylate capsule
Sponsor: Henan Cancer Hospital
Not yet recruiting -
Endoscopic Surgery in the Treatment of Soft Tissue Sarcoma in Nasal and Paranasal Sinus
Posted: November 14th, 2022, 3:00pm GMT
Conditions: Sarcoma,Soft Tissue; Nasal Cavity Cancer; Paranasal Sinus Cancer; Surgery
Intervention: Procedure: endoscopic surgery
Sponsor: Eye & ENT Hospital of Fudan University
Recruiting -
Cryoablation for Advanced Bone and Soft Tissue Tumors
Posted: November 14th, 2022, 3:00pm GMT
Conditions: Sarcoma; Cryoablation
Intervention: Procedure: Cryoablation
Sponsor: Henan Cancer Hospital
Recruiting -
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
Posted: November 4th, 2022, 2:00pm GMT
Conditions: Pancreatic Ductal Adenocarcinoma (PDAC); Squamous Cell Carcinoma of Head and Neck; Colorectal Cancer; Gastric Cancer; Ewing Sarcoma; NTSR1 Expressing Solid Tumours; Neuroendocrine Differentiated (NED) Prostate Cancer
Interventions: Drug: [225]-FPI-2059; Drug: [111In]-FPI-2058
Sponsor: Fusion Pharmaceuticals Inc.
Recruiting -
A Phase II Study by Using CICS-1 and SPM-011 Commissioned by CICS and STELLA PHARMA
Posted: November 1st, 2022, 2:00pm GMT
Condition: Unresectable Angiosarcoma
Intervention: Radiation: BNCT
Sponsors: Stella Pharma Corporation; Cancer Intelligence Care Systems, Inc.
Recruiting -
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
Posted: October 25th, 2022, 2:00pm GMT
Conditions: Colorectal Cancer; Metastatic Colorectal Cancer
Interventions: Drug: Onvansertib; Drug: FOLFIRI; Drug: Bevacizumab
Sponsor: Cardiff Oncology
Recruiting -
Doxil/Caelyx BE Study
Posted: October 5th, 2022, 2:00pm GMT
Conditions: Ovarian Cancer; AIDS-related Kaposi Sarcoma; Multiple Myeloma; Metastatic Breast Cancer
Intervention: Drug: DOXIL/CAELYX
Sponsor: Baxter Healthcare Corporation
Not yet recruiting -
An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas
Posted: September 29th, 2022, 2:00pm GMT
Conditions: Recurrent Soft Tissue Sarcoma; Resectable Soft Tissue Sarcoma; Soft Tissue Sarcoma
Interventions: Drug: Fluorodopa F 18; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Radiation: Radiation Therapy; Procedure: Surgical Procedure
Sponsor: Mayo Clinic
Recruiting -
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
Posted: September 29th, 2022, 2:00pm GMT
Conditions: Gynecologic Cancer; Carcinoma; Uterine Cancer; Endometrial Cancer
Intervention: Drug: Cabo + Dostarlimab
Sponsor: University of Alabama at Birmingham
Not yet recruiting -
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Posted: September 14th, 2022, 2:00pm GMT
Conditions: Breast Cancer; Glioblastoma; Head and Neck Squamous Cell Carcinoma; Malignant Mesothelioma; Non-small Cell Lung Cancers; Sarcoma
Intervention: Drug: PRT3645
Sponsor: Prelude Therapeutics
Recruiting -
Individualized Prehabilitation for Enhancing Recovery and Surgical Outcomes in Patients Undergoing Radiotherapy and Surgery for Soft Tissue Sarcoma
Posted: September 2nd, 2022, 2:00pm GMT
Conditions: Soft Tissue Sarcoma; Stage I Soft Tissue Sarcoma of the Trunk and Extremities; Stage II Soft Tissue Sarcoma of the Trunk and Extremities; Stage III Soft Tissue Sarcoma of the Trunk and Extremities
Interventions: Procedure: Computed Tomography; Other: Educational Intervention; Procedure: Magnetic Resonance Imaging; Procedure: Physical Therapy; Other: Questionnaire Administration; Other: Telemedicine
Sponsor: Mayo Clinic
Recruiting -
A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA
Posted: August 25th, 2022, 2:00pm GMT
Conditions: Sarcoma,Soft Tissue; Sarcoma Uterus
Intervention: Drug: Niraparib
Sponsors: Memorial Sloan Kettering Cancer Center; GlaxoSmithKline
Recruiting -
Pembrolizumab Combined With Radiotherapy for Metastatic Sarcoma
Posted: August 4th, 2022, 2:00pm GMT
Condition: Sarcoma, Soft Tissue
Interventions: Drug: Pembrolizumab; Radiation: Radiation therapy
Sponsor: University of California, Irvine
Recruiting -
YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma
Posted: July 7th, 2022, 2:00pm GMT
Conditions: Advanced Sarcoma; Metastatic Sarcoma; Soft Tissue Sarcoma
Interventions: Drug: YH001; Drug: Envafolimab; Drug: Doxorubicin
Sponsor: Tracon Pharmaceuticals Inc.
Recruiting -
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Posted: July 1st, 2022, 2:00pm GMT
Conditions: Sarcoma, Ewing; Neoplasm Metastasis
Interventions: Drug: Abemaciclib; Drug: Irinotecan; Drug: Temozolomide
Sponsor: Eli Lilly and Company
Recruiting -
Circulating " Cancer Cells / Macrophage " HYbrid Cells in Patients With Sarcoma, Part 2
Posted: June 22nd, 2022, 2:00pm GMT
Condition: Leiomyosarcoma
Intervention: Other: Blood samples will be collected at different times.
Sponsors: Institut Claudius Regaud; Fondation ARC
Recruiting -
Theranostics in Soft Tissue Sarcoma Using a Vascular Disruption Approach
Posted: June 15th, 2022, 2:00pm GMT
Condition: Soft Tissue Sarcoma
Interventions: Drug: Ga-68-PSMA-11 PET/CT; Drug: Lu-177-ITG-PSMA-1
Sponsor: John O. Prior
Not yet recruiting -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
Posted: June 10th, 2022, 2:00pm GMT
Conditions: Nasopharyngeal Carcinoma; Castrate Resistant Prostate Cancer; Gastric Cancer; Ovarian Clear Cell Carcinoma; Mesothelioma; Sarcoma; Non Hodgkin Lymphoma; B Cell Lymphoma; Epithelioid Sarcoma
Intervention: Drug: APG-5918
Sponsor: Ascentage Pharma Group Inc.
Recruiting -
Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma
Posted: June 9th, 2022, 2:00pm GMT
Conditions: Kaposi Sarcoma; HIV-1-infection
Interventions: Drug: Pegylated liposomal doxorubicin; Drug: Paclitaxel
Sponsors: AIDS Malignancy Consortium; National Cancer Institute (NCI)
Not yet recruiting -
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
Posted: June 7th, 2022, 2:00pm GMT
Conditions: Atypical Teratoid Rhabdoid Tumor; INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors; SMARCA4-deficient Primary CNS Malignant Tumors; Malignant Rhabdoid Tumor (MRT); Rhabdoid Tumor of the Kidney (RTK); Epithelioid Sarcoma; Chordoma
Interventions: Drug: Tazemetostat; Drug: Nivolumab; Drug: Ipilimumab
Sponsors: Susan Chi, MD; Bristol-Myers Squibb; Epizyme, Inc.
Recruiting -
A Dose-Escalation and Dose-Expansion Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors
Posted: May 25th, 2022, 2:00pm GMT
Condition: Advanced Solid Tumors
Interventions: Drug: ADCT-601; Drug: Gemcitabine
Sponsor: ADC Therapeutics S.A.
Recruiting -
cfMeDIP-seq Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Posted: May 9th, 2022, 2:00pm GMT
Conditions: Brain Cancer; Breast Cancer; Bladder Cancer; Cervical Cancer; Colorectal Cancer; Endometrial Cancer; Esophageal Cancer; Stomach Cancer; Head and Neck Cancer; Hepatobiliary Cancer; Leukemia; Lung Cancer; Lymphoma; Multiple Myeloma; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Renal Cancer; Sarcoma; Thyroid Cancer
Intervention:
Sponsor: Adela, Inc.
Recruiting -
Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors
Posted: May 5th, 2022, 2:00pm GMT
Conditions: Cancer; Cancer of Pancreas; Sarcoma; Hepatic Metastasis; Solid Tumor
Intervention: Drug: STI-1386
Sponsor: Sorrento Therapeutics, Inc.
Not yet recruiting -
Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma, the Axiom Study
Posted: April 19th, 2022, 2:00pm GMT
Conditions: Advanced Alveolar Soft Part Sarcoma; Advanced Soft Tissue Sarcoma; Metastatic Alveolar Soft Part Sarcoma; Unresectable Alveolar Soft Part Sarcoma
Interventions: Biological: Atezolizumab; Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Drug: Selinexor
Sponsor: National Cancer Institute (NCI)
Recruiting -
A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma
Posted: April 5th, 2022, 2:00pm GMT
Condition: Osteosarcoma
Interventions: Biological: SCRI-E2CAR_EGFRtv1; Drug: UB_TT170
Sponsors: Seattle Children's Hospital; Umoja BioPharma, Inc.
Recruiting -
A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue Sarcoma
Posted: March 31st, 2022, 2:00pm GMT
Condition: Soft Tissue Sarcoma
Intervention: Combination Product: LVGN6051 and Anlotinib
Sponsor: Lyvgen Biopharma Holdings Limited
Recruiting -
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Posted: March 31st, 2022, 2:00pm GMT
Conditions: Embryonal Rhabdomyosarcoma; Fusion-Negative Alveolar Rhabdomyosarcoma; Spindle Cell/Sclerosing Rhabdomyosarcoma
Interventions: Drug: Cyclophosphamide; Biological: Dactinomycin; Radiation: Radiation Therapy; Drug: Vincristine
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting -
Habitat Escalated Adaptive Therapy (HEAT), With Neoadjuvant Radiation for Soft Tissue Sarcoma
Posted: March 29th, 2022, 2:00pm GMT
Condition: High Grade Sarcoma
Interventions: Radiation: Intensity Modulated Radiation Therapy (IMRT); Diagnostic Test: MRI
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Viewray Inc.
Recruiting -
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
Posted: March 18th, 2022, 2:00pm GMT
Conditions: Atypical Teratoid/Rhabdoid Tumor; Epithelioid Sarcoma; Kidney Medullary Carcinoma; Malignant Solid Neoplasm; Poorly Differentiated Chordoma; Recurrent Atypical Teratoid/Rhabdoid Tumor; Recurrent Chordoma; Recurrent Epithelioid Sarcoma; Recurrent Kidney Medullary Carcinoma; Recurrent Malignant Solid Neoplasm; Recurrent Rhabdoid Tumor; Refractory Atypical Teratoid/Rhabdoid Tumor; Refractory Chordoma; Refractory Epithelioid Sarcoma; Refractory Kidney Medullary Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Rhabdoid Tumor; Rhabdoid Tumor
Interventions: Biological: Atezolizumab; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Other: Fludeoxyglucose F-18; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Biological: Tiragolumab; Procedure: X-Ray Imaging
Sponsor: National Cancer Institute (NCI)
Recruiting -
A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
Posted: March 8th, 2022, 3:00pm GMT
Condition: Leiomyosarcoma
Interventions: Drug: Unesbulin; Drug: Dacarbazine; Other: Placebo
Sponsor: PTC Therapeutics
Recruiting -
Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Posted: February 25th, 2022, 3:00pm GMT
Conditions: Endometrial Serous Adenocarcinoma; Uterine Corpus Carcinosarcoma
Interventions: Drug: Carboplatin; Procedure: Echocardiography; Drug: Hyaluronidase-zzxf/Pertuzumab/Trastuzumab; Procedure: Multigated Acquisition Scan; Drug: Paclitaxel; Other: Quality-of-Life Assessment; Drug: Trastuzumab/Hyaluronidase-oysk
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting -
Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas
Posted: February 23rd, 2022, 3:00pm GMT
Conditions: MPNST; NF1; Sarcoma
Intervention: Drug: Selumetinib
Sponsors: University of Alabama at Birmingham; United States Department of Defense
Not yet recruiting -
(VELA) Study of BLU-222 in Advanced Solid Tumors
Posted: February 23rd, 2022, 3:00pm GMT
Conditions: ER+ Breast Cancer; CCNE1 Amplification; HER2-negative Breast Cancer; Advanced Solid Tumor; Ovarian Cancer; Endometrial Cancer; Gastric Cancer; Esophageal Adenocarcinoma; Carcinosarcoma
Interventions: Drug: BLU-222; Drug: Carboplatin; Drug: Ribociclib; Drug: Fulvestrant
Sponsor: Blueprint Medicines Corporation
Recruiting -
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
Posted: February 14th, 2022, 3:00pm GMT
Conditions: Gastric Cancer; Renal Cell Carcinoma; Melanoma; Sarcoma; Testicular Germ Cell Tumor; Cervical Cancer; Mesothelioma; Non Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma
Interventions: Drug: HFB200301; Drug: Tislelizumab
Sponsor: HiFiBiO Therapeutics
Recruiting -
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Posted: February 11th, 2022, 3:00pm GMT
Conditions: Metastatic Malignant Neoplasm in the Lung; Metastatic Osteosarcoma; Osteosarcoma
Interventions: Other: Questionnaire Administration; Procedure: Thoracoscopy; Procedure: Thoracotomy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting -
Brightline-1: A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Posted: February 1st, 2022, 3:00pm GMT
Condition: Liposarcoma, Dedifferentiated
Interventions: Drug: BI 907828; Drug: Doxorubicin
Sponsor: Boehringer Ingelheim
Recruiting -
Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
Posted: January 27th, 2022, 3:00pm GMT
Condition: Relapsed Sarcomas
Interventions: Drug: Disulfiram; Drug: Copper Gluconate; Drug: Liposomal Doxorubicin (Doxil)
Sponsor: Case Comprehensive Cancer Center
Recruiting -
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
Posted: January 20th, 2022, 3:00pm GMT
Condition: Colorectal Cancer (CRC)
Interventions: Drug: Sotorasib; Drug: Panitumumab; Drug: Trifluridine and Tipiracil; Drug: Regorafenib
Sponsor: Amgen
Recruiting -
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Posted: January 20th, 2022, 3:00pm GMT
Condition: Solid Tumors With PTCH1 Loss-of-function Mutations
Intervention: Drug: ENV-101 (taladegib)
Sponsor: Endeavor Biomedicines, Inc.
Recruiting -
Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma.
Posted: January 12th, 2022, 3:00pm GMT
Condition: Soft Tissue Sarcoma
Interventions: Drug: Albumin-Bound Paclitaxel; Drug: Camrelizumab
Sponsor: Henan Cancer Hospital
Recruiting -
Niraparib for the Treatment of Leiomyosarcoma
Posted: December 30th, 2021, 3:00pm GMT
Conditions: Locally Advanced Leiomyosarcoma; Metastatic Leiomyosarcoma; Stage III Retroperitoneal Sarcoma AJCC v8; Stage IIIA Retroperitoneal Sarcoma AJCC v8; Stage IIIB Retroperitoneal Sarcoma AJCC v8; Stage IV Retroperitoneal Sarcoma AJCC v8; Unresectable Leiomyosarcoma
Intervention: Drug: Niraparib Tosylate Monohydrate
Sponsor: David Liebner, MD
Not yet recruiting -
Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC
Posted: December 22nd, 2021, 3:00pm GMT
Conditions: Nasopharyngeal Carcinoma; EBV-Related Gastric Carcinoma; EBV-Related Leiomyosarcoma; EBV Related Carcinoma; EBV-Related Sarcoma
Interventions: Drug: Nanatinostat; Drug: Pembrolizumab; Drug: Valganciclovir
Sponsor: Viracta Therapeutics, Inc.
Recruiting -
A Study of PRT2527 in Participants With Advanced Solid Tumors
Posted: December 16th, 2021, 3:00pm GMT
Conditions: Sarcoma; Castrate Resistant Prostate Cancer; Hormone Receptor Positive HER2 Negative Breast Cancer; Non-small Cell Lung Cancer; Solid Tumors With Known MYC Amplification
Intervention: Drug: PRT2527
Sponsor: Prelude Therapeutics
Recruiting -
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Posted: November 26th, 2021, 3:00pm GMT
Conditions: Neuroblastoma; CNS Tumor; Sarcoma
Intervention: Drug: Cabozantinib
Sponsors: Nationwide Children's Hospital; Exelixis
Recruiting -
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
Posted: November 23rd, 2021, 3:00pm GMT
Conditions: SCLC; Malignant Melanoma; Sarcoma
Intervention: Drug: GD2-SADA:177Lu-DOTA Complex
Sponsor: Y-mAbs Therapeutics
Recruiting -
The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors
Posted: November 23rd, 2021, 3:00pm GMT
Conditions: Cancer; Cancer Metastatic; Neoplasms; Breast Cancer; Lung Cancer; Thyroid Cancer; Lymphoma; Lymphoma, Non-Hodgkin; Hodgkin Lymphoma; Leukemia; Sarcoma; Skin Cancer; Bone Cancer; Gynecologic Cancer; Pancreas Cancer; Multiple Myeloma; Colorectal Cancer; Gastrointestinal Cancer; Prostate Cancer; Glioblastoma; Brain Cancer; Head and Neck Cancer
Intervention: Behavioral: Virtual group based physical activity (BurnAlong) and Social Media Discussion Board
Sponsors: Cedars-Sinai Medical Center; Walter Reed National Military Medical Center
Recruiting -
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
Posted: November 15th, 2021, 3:00pm GMT
Conditions: Hepatocellular Carcinoma; Squamous Cell Carcinoma of the Lung; Merkel Cell Carcinoma; Myxoid/Round Cell Liposarcoma
Intervention: Biological: CAR-GPC3 T Cells
Sponsors: SOTIO, LLC; SOTIO Biotech
Recruiting -
ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma
Posted: November 11th, 2021, 3:00pm GMT
Conditions: Leiomyosarcoma; Liposarcoma
Intervention: Drug: ATX-101
Sponsor: Columbia University
Recruiting -
HIFU Ablation of Soft Tissue Sarcoma
Posted: November 8th, 2021, 3:00pm GMT
Conditions: Soft Tissue Sarcoma; Desmoid; Abdominal
Interventions: Device: High Intensity Focused Ultrasound Ablation; Diagnostic Test: Tumour Biopsy and Venous Blood Tests
Sponsors: Oxford University Hospitals NHS Trust; Surgical Intervention Trials Unit (trial oversight); NIHR Direct Delivery Team (implementation); Oxford Radiology Research Unit (implementation)
Recruiting -
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Hepatocellular Carcinoma
Posted: November 2nd, 2021, 2:00pm GMT
Conditions: Liver Cell Carcinoma; Solid Tumor; Wilms Tumor; Malignant Rhabdoid Tumor; Yolk Sac Tumor; Rhabdomyosarcoma; Liposarcoma; Embryonal Sarcoma of the Liver
Interventions: Genetic: CATCH T cells; Drug: Cytoxan; Drug: Fludara
Sponsors: Baylor College of Medicine; Center for Cell and Gene Therapy, Baylor College of Medicine; The Methodist Hospital Research Institute
Recruiting -
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors
Posted: October 8th, 2021, 2:00pm GMT
Conditions: Recurrent Alveolar Rhabdomyosarcoma; Recurrent Ewing Sarcoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Refractory Alveolar Rhabdomyosarcoma; Refractory Ewing Sarcoma; Refractory Lymphoma; Refractory Malignant Solid Neoplasm
Intervention: Drug: Elimusertib
Sponsor: National Cancer Institute (NCI)
Recruiting -
Camsirubicin + Pegfilgrastim to Determine MTD in ASTS
Posted: September 14th, 2021, 2:00pm GMT
Condition: Advanced Soft-tissue Sarcoma
Intervention: Drug: Camsirubicin
Sponsor: Monopar Therapeutics
Recruiting -
IACS-6274 With or Without Pembrolizumab for the Treatment of Advanced Solid Tumors
Posted: September 10th, 2021, 2:00pm GMT
Conditions: Advanced Endometrial Carcinoma; Advanced Head and Neck Squamous Cell Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Melanoma; Advanced Ovarian Clear Cell Adenocarcinoma; Chondrosarcoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Refractory Endometrial Carcinoma; Refractory Head and Neck Squamous Cell Carcinoma; Refractory High Grade Ovarian Serous Adenocarcinoma; Refractory Melanoma; Refractory Ovarian Clear Cell Adenocarcinoma; Stage III Ovarian Cancer AJCC v8; Stage III Uterine Corpus Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Uterine Corpus Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Uterine Corpus Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IIIC Uterine Corpus Cancer AJCC v8; Stage IIIC1 Uterine Corpus Cancer AJCC v8; Stage IIIC2 Uterine Corpus Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8
Interventions: Drug: Glutaminase Inhibitor IPN60090; Drug: Bevacizumab; Drug: Paclitaxel
Sponsor: M.D. Anderson Cancer Center
Recruiting -
Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for the Management of Pelvic Sarcomas Involving the Bone, the PROSPER Study
Posted: September 2nd, 2021, 2:00pm GMT
Conditions: Bone Sarcoma; Chondrosarcoma; Chordoma; Ewing Sarcoma of Bone; Pelvic Rhabdomyosarcoma
Interventions: Other: Electronic Health Record Review; Other: Quality-of-Life Assessment
Sponsor: Mayo Clinic
Recruiting -
Milademetan in Advanced/Metastatic Solid Tumors
Posted: August 19th, 2021, 2:00pm GMT
Conditions: Solid Tumors; Head and Neck Carcinoma; Cholangiocarcinoma; Sarcoma; Lung Adenocarcinoma; Bladder Urothelial Carcinoma; Stomach Adenocarcinoma; Breast Cancer Invasive; Ovarian Carcinoma; Cervical Cancer; Non Small Cell Lung Cancer; Gastric Cancer; Biliary Tract Cancer; Melanoma; Pancreas Cancer; MDM2 Gene Amplification; Testicular Germ Cell Tumor; Adrenocortical Carcinoma
Intervention: Drug: RAIN-32
Sponsor: Rain Oncology Inc
Recruiting -
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Posted: August 11th, 2021, 2:00pm GMT
Conditions: Bile Duct Cancer; Gall Bladder Cancer; Breast Cancer; Neuroendocrine Tumors; Ovarian Cancer; Pancreatic Adenocarcinoma; Soft Tissue Sarcoma; Vulvar Cancer; Prostate Cancer
Interventions: Drug: Atezolizumab; Drug: Tivozanib
Sponsors: University of Florida; Genentech, Inc.; Aveo Oncology Pharmaceuticals
Recruiting -
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
Posted: August 11th, 2021, 2:00pm GMT
Conditions: Ovarian Cancer; Ovarian Neoplasms; Ovarian Carcinoma; Endometrial Cancer; Colorectal Cancer; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma; TNBC - Triple-Negative Breast Cancer; Triple Negative Breast Cancer; Cholangiocarcinoma; Bile Duct Cancer; Colon Cancer; Colon Cancer Stage; Colon Neoplasm; Colon Adenocarcinoma; Colon Rectal Cancer; Colon Cancer Liver Metastasis; Colorectal Neoplasms; Colorectal Carcinoma; Colorectal Adenocarcinoma; Colorectal Cancer Metastatic; Colorectal Cancer Stage IV; Rectum Cancer; Rectum Neoplasm; Rectum Carcinoma; Rectal Cancer; Rectal Neoplasms; Rectal Adenocarcinoma; Rectal Cancer Stage; Rectal Cancer Metastatic; Rectal Cancer Stage III; Esophagus Cancer; Esophageal Cancer; Esophageal Neoplasms; Gastric Cancer Stage; Breast Cancer; Breast Neoplasm; Breast Adenocarcinoma; Breast Cancer Stage IV; Breast Cancer Stage; Breast Cancer Metastatic; Breast Cancer Invasive; Triple Negative Breast Neoplasms; Intrahepatic Cholangiocarcinoma; Intrahepatic Cholangiocarcinoma Recurrent; Hilar Cholangiocarcinoma; Distal Cholangiocarcinoma; Ovary Cancer; Ovary Neoplasm; Ovary Disease; Ovary Metastasis; Ovarian Diseases; Ovarian Cancer Stage; Ovarian Epithelial Cancer; Ovarian Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Neoplasm Epithelial; Ovarian Cancer Recurrent; Endometrial Diseases; Endometrial Adenocarcinoma; Endometrial Carcinosarcoma; Endometrial Clear Cell Adenocarcinoma; Endometrioid Adenocarcinoma; Endometrial Neoplasms; Endometrial Cancer Recurrent; Endometrioid Tumor; Fallopian Tube Cancer; Peritoneal Cancer
Intervention: Drug: ELU001
Sponsor: Elucida Oncology
Recruiting -
A Study to Learn About the Study Medicine (Called TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma
Posted: August 9th, 2021, 2:00pm GMT
Condition: Leiomyosarcoma
Interventions: Drug: TTI-621; Drug: Doxorubicin
Sponsor: Pfizer
Recruiting -
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Posted: August 6th, 2021, 2:00pm GMT
Conditions: Sarcoma; HER-2 Protein Overexpression
Interventions: Genetic: cells; Drug: Pembrolizumab Injectable Product; Drug: Nivolumab Injectable Product; Drug: Lymphodepletion Chemotherapy
Sponsors: Baylor College of Medicine; Center for Cell and Gene Therapy, Baylor College of Medicine; The Faris Foundation USA; Stand Up To Cancer; Triumph Over Kid Cancer Foundation; St. Baldrick's Foundation
Recruiting -
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
Posted: August 6th, 2021, 2:00pm GMT
Conditions: Alveolar Rhabdomyosarcoma; Botryoid-Type Embryonal Rhabdomyosarcoma; Embryonal Rhabdomyosarcoma; Metastatic Embryonal Rhabdomyosarcoma; Metastatic Rhabdomyosarcoma; Solid Alveolar Rhabdomyosarcoma; Spindle Cell Rhabdomyosarcoma; Spindle Cell/Sclerosing Rhabdomyosarcoma
Interventions: Drug: Cyclophosphamide; Biological: Dactinomycin; Radiation: Radiation Therapy; Drug: Vincristine Sulfate; Drug: Vinorelbine Tartrate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting -
Osteosarcoma Maintenance Therapy With OST31-164
Posted: July 22nd, 2021, 2:00pm GMT
Condition: Bone Cancer
Intervention: Drug: OST31-164
Sponsor: George Clinical Pty Ltd
Recruiting -
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Posted: July 21st, 2021, 2:00pm GMT
Conditions: Pancreatic Cancer; Colorectal Cancer; Non-small Cell Lung Cancer; Breast Cancer; Head and Neck Cancer; Soft Tissue Sarcoma; Ovarian Cancer; Bladder Cancer
Intervention: Drug: AVA6000
Sponsor: Avacta Life Sciences Ltd
Recruiting -
Natural History of KSHV-Associated Multicentric Castleman s Disease
Posted: July 20th, 2021, 2:00pm GMT
Condition: Multicentric Castleman s Disease
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting -
SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma
Posted: July 19th, 2021, 2:00pm GMT
Condition: Advanced Dedifferentiated Liposarcoma
Interventions: Drug: Abemaciclib; Drug: Placebo
Sponsors: Sarcoma Alliance for Research through Collaboration; Eli Lilly and Company
Recruiting -
Study of INBRX-109 in Conventional Chondrosarcoma
Posted: July 6th, 2021, 2:00pm GMT
Condition: Conventional Chondrosarcoma
Interventions: Drug: INBRX-109; Drug: Placebo
Sponsor: Inhibrx, Inc.
Recruiting -
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
Posted: June 28th, 2021, 2:00pm GMT
Condition: Kaposi Sarcoma
Intervention: Drug: Abemaciclib
Sponsor: National Cancer Institute (NCI)
Recruiting -
Localized Leiomyosarcoma Biomarker Protocol
Posted: June 14th, 2021, 2:00pm GMT
Condition: Leiomyosarcoma
Intervention: Other: Blood and Tissue collection
Sponsors: University of Michigan Rogel Cancer Center; National Cancer Institute (NCI)
Not yet recruiting -
Exercise and Soft Tissue Sarcoma
Posted: June 10th, 2021, 2:00pm GMT
Condition: Soft Tissue Sarcoma
Intervention: Other: neoadjuvant exercise therapy
Sponsors: Duke University; University of North Carolina, Chapel Hill
Recruiting -
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Posted: June 9th, 2021, 2:00pm GMT
Conditions: Fallopian Tube Carcinosarcoma; Fallopian Tube Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Ovarian Carcinosarcoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
Interventions: Biological: Bevacizumab; Biological: Pegcetacoplan; Biological: Pembrolizumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsor: Roswell Park Cancer Institute
Not yet recruiting -
Tazemetostat in Malignant Peripheral Nerve Sheath Tumors
Posted: June 8th, 2021, 2:00pm GMT
Condition: Peripheral Nerve Sheath Tumor
Intervention: Drug: Tazemetostat
Sponsors: University of Florida; Epizyme, Inc.
Recruiting -
Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors
Posted: May 26th, 2021, 2:00pm GMT
Conditions: Solid Tumor, Adult; Brain Tumor, Primary; Desmoplastic Small Round Cell Tumor
Intervention: Drug: PBI-200
Sponsor: Pyramid Biosciences
Recruiting -
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
Posted: May 26th, 2021, 2:00pm GMT
Conditions: Viral Associated Malignancies; Kaposi Sarcoma; EBV/KSHV-associated Lymphomas
Interventions: Drug: Pomalidomide; Drug: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting -
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Posted: May 21st, 2021, 2:00pm GMT
Conditions: Pediatric Solid Tumor; Osteosarcoma; Rhabdomyosarcoma; Neuroblastoma; Ewing Sarcoma; Wilms Tumor; Adrenocortical Cancer; Desmoplastic Small Round Cell Tumor; Germ Cell Cancer; Rhabdoid Tumor; Clear Cell Sarcoma; Hepatoblastoma; Melanoma; Carcinoma; Malignant Peripheral Nerve Sheath Tumors; Soft Tissue Sarcoma
Interventions: Drug: Fludarabine; Drug: Cyclophosphamide; Drug: MESNA; Drug: B7-H3 CAR T cells
Sponsor: St. Jude Children's Research Hospital
Recruiting -
Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors
Posted: May 18th, 2021, 2:00pm GMT
Conditions: Sarcoma, Ewing; Rhabdomyosarcoma
Interventions: Drug: PEN-866; Drug: Vincristine; Drug: Temozolomide
Sponsor: National Cancer Institute (NCI)
Not yet recruiting -
Study of Liposomal Annamycin for the Treatment of Subjects With Soft-Tissue Sarcomas (STS) With Pulmonary Metastases
Posted: May 14th, 2021, 2:00pm GMT
Conditions: Sarcoma,Soft Tissue; Pulmonary Metastasis
Intervention: Drug: Liposomal Annamycin (L-Annamycin)
Sponsor: Moleculin Biotech, Inc.
Recruiting -
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
Posted: April 21st, 2021, 2:00pm GMT
Conditions: Minimal Residual Disease; KRAS G12D; KRAS G12R; NRAS G12D; NRAS G12R; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; Non-small Cell Lung Cancer; Ovarian Cancer; Cholangiocarcinoma; Bile Duct Cancer; Gallbladder Carcinoma
Intervention: Drug: ELI-002 2P
Sponsor: Elicio Therapeutics
Recruiting -
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
Posted: March 18th, 2021, 2:00pm GMT
Conditions: Osteosarcoma; Osteosarcoma in Children; Osteosarcoma Recurrent; Osteosarcoma Metastatic
Interventions: Drug: Regorafenib 40 MG; Drug: Regorafenib 20MG; Drug: Nivolumab
Sponsor: Sarcoma Alliance for Research through Collaboration
Recruiting -
Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma.
Posted: March 1st, 2021, 3:00pm GMT
Condition: Kaposiform Hemangioendothelioma
Intervention: Drug: Sirolimus
Sponsor: West China Hospital
Recruiting -
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
Posted: February 24th, 2021, 3:00pm GMT
Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: ION363; Drug: Placebo
Sponsor: Ionis Pharmaceuticals, Inc.
Recruiting -
The Sarcoma Biology and Outcome Project
Posted: February 17th, 2021, 3:00pm GMT
Conditions: Sarcoma; Malignant Mesenchymoma; Sarcoma of Bone and Connective Tissue
Intervention:
Sponsor: Prof. Dr. Richard F Schlenk
Recruiting -
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
Posted: February 12th, 2021, 3:00pm GMT
Conditions: High Risk Neuroblastoma; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Refractory Neuroblastoma; Resectable Osteosarcoma
Interventions: Procedure: Biospecimen Collection; Procedure: Bone Marrow Aspiration; Procedure: Computed Tomography; Biological: Dinutuximab; Procedure: Magnetic Resonance Imaging; Biological: Magrolimab; Procedure: Resection
Sponsor: National Cancer Institute (NCI)
Recruiting -
Efficacy and Safety of L19TNF in Previously Treated Patients With Advanced Stage or Metastatic Soft-tissue Sarcoma
Posted: February 1st, 2021, 3:00pm GMT
Condition: Soft Tissue Sarcoma
Interventions: Drug: Dacarbazine; Drug: onfekafusp alfa
Sponsor: Philogen S.p.A.
Recruiting